Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection

Roy M. Gulick, M.D., M.P.H., Heather J. Ribaudo, Ph.D., Cecilia M. Shikuma, M.D., Stephanie Lustgarten, M.S., Kathleen E. Squires, M.D., William A. Meyer, III, Ph.D., Edward P. Acosta, Pharm.D., Bruce R. Schackman, Ph.D., Christopher D. Pilcher, M.D., Robert L. Murphy, M.D., William E. Maher, M.D., Mallory D. Witt, M.D., Richard C. Reichman, M.D., Sally Snyder, B.S., Karin L. Klingman, M.D., Daniel R. Kuritzkes, M.D., for the AIDS Clinical Trials Group Study A5095 Team

New England Journal of Medicine 2004; 350;1850-1861.

Copyright ©  2004 Massachusetts Medical Society